Cytosorbents (CTSO) Return on Capital Employed (2011 - 2026)

Cytosorbents' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 53.34% for Q1 2026.

• Quarterly Return on Capital Employed fell 1348.0% year-over-year to 53.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53.34% (down 1348.0% YoY) and the FY2025 annual result came in at 40.89%, down 11.0% from the prior year.
• Return on Capital Employed was 53.34% for Q1 2026 at Cytosorbents, down from 41.84% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 37.43% in Q3 2025 and bottomed at 86.14% in Q4 2023.
• A 5-year average of 55.27% and a median of 53.34% in 2026 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 4285 bps — and 2024, when it surged 4258 bps.
• Cytosorbents' Return on Capital Employed stood at 59.43% in 2022, then sank by 45 bps to 86.14% in 2023, then surged by 49 bps to 43.56% in 2024, then gained by 4 bps to 41.84% in 2025, then slipped by 28 bps to 53.34% in 2026.
• Business Quant data shows CTSO's Return on Capital Employed at 53.34% in Q1 2026, 41.84% in Q4 2025, and 37.43% in Q3 2025.